{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:23:13Z","timestamp":1780514593527,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04899-5","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:11:49Z","timestamp":1778663509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic and pharmacogenomic profile of capecitabine and oxaliplatin in a patient with gastric cancer undergoing hemodialysis: a case report"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0235-7615","authenticated-orcid":false,"given":"Yuki","family":"Nakano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-2068","authenticated-orcid":false,"given":"Toshinori","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2898-6369","authenticated-orcid":false,"given":"Nao","family":"Nishijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5883-5842","authenticated-orcid":false,"given":"Yugo","family":"Uematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Imada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Naritomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2755-8341","authenticated-orcid":false,"given":"Fumihiko","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9412-0868","authenticated-orcid":false,"given":"Naohito","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4329-8161","authenticated-orcid":false,"given":"Tadashi","family":"Hayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Yasunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Hasuwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9190-4600","authenticated-orcid":false,"given":"Kosuke","family":"Masutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"4899_CR1","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1186\/s12889-024-19104-6","volume":"24","author":"JL Lin","year":"2024","unstructured":"Lin JL, Lin JX, Lin GT, Huang CM, Zheng CH, Xie JW, Wang JB et al (2024) Global incidence and mortality trends of gastric cancer and predicted mortality of gastric cancer by 2035. BMC Public Health 24:1763. https:\/\/doi.org\/10.1186\/s12889-024-19104-6","journal-title":"BMC Public Health"},{"key":"4899_CR2","doi-asserted-by":"publisher","first-page":"e0122856","DOI":"10.1371\/journal.pone.0122856","volume":"10","author":"MY Lin","year":"2015","unstructured":"Lin MY, Kuo MC, Hung CC, Wu WJ, Chen LT, Yu ML, Hsu CC et al (2015) Association of dialysis with the risks of cancers. PLoS ONE 10:e0122856. https:\/\/doi.org\/10.1371\/journal.pone.0122856","journal-title":"PLoS ONE"},{"key":"4899_CR3","doi-asserted-by":"publisher","first-page":"e0207756","DOI":"10.1371\/journal.pone.0207756","volume":"13","author":"HJ Oh","year":"2018","unstructured":"Oh HJ, Lee HA, Moon CM, Ryu DR (2018) Incidence risk of various types of digestive cancers in patients with pre-dialytic chronic kidney disease: a nationwide population-based cohort study. PLoS ONE 13:e0207756. https:\/\/doi.org\/10.1371\/journal.pone.0207756","journal-title":"PLoS ONE"},{"key":"4899_CR4","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.ekir.2022.06.005","volume":"7","author":"B Sprangers","year":"2022","unstructured":"Sprangers B, Perazella MA, Lichtman SM, Rosner MH, Jhaveri KD (2022) Improving cancer care for patients with CKD: the need for changes in clinical trials. Kidney Int Rep 7:1939\u20131950. https:\/\/doi.org\/10.1016\/j.ekir.2022.06.005","journal-title":"Kidney Int Rep"},{"key":"4899_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/annonc\/mds344","volume":"24","author":"N Janus","year":"2013","unstructured":"Janus N, Launay-Vacher V, Thyss A, Boulanger H, Moranne O, Islam MS, Durande JP et al (2013) Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol 24:501\u2013507. https:\/\/doi.org\/10.1093\/annonc\/mds344","journal-title":"Ann Oncol"},{"key":"4899_CR6","doi-asserted-by":"publisher","first-page":"e1704","DOI":"10.1002\/onco.13907","volume":"26","author":"DV Catenacci","year":"2021","unstructured":"Catenacci DV, Chao J, Muro K, Al-Batran SE, Klempner SJ, Wainberg ZA, Shah MA et al (2021) Toward a treatment sequencing strategy: a systematic review of treatment regimens in advanced gastric cancer\/gastroesophageal junction adenocarcinoma. Oncologist 26:e1704\u2013e1729. https:\/\/doi.org\/10.1002\/onco.13907","journal-title":"Oncologist"},{"key":"4899_CR7","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1111\/cas.14553","volume":"111","author":"K Yokoi","year":"2020","unstructured":"Yokoi K, Nakajima Y, Matsuoka H, Shinkai Y, Ishihara T, Maeda Y, Kato T et al (2020) Impact of DPYD, DPYS, and UPB1 gene variations on severe drug-related toxicity in patients with cancer. Cancer Sci 111:3359\u20133366. https:\/\/doi.org\/10.1111\/cas.14553","journal-title":"Cancer Sci"},{"key":"4899_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36\u201346. https:\/\/doi.org\/10.1056\/NEJMoa073149","journal-title":"N Engl J Med"},{"key":"4899_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4137\/cmo.s412","volume":"2","author":"K Katsumata","year":"2008","unstructured":"Katsumata K, Sumi T, Wada T, Mori Y, Hisada M, Kawakita H, Enomoto M et al (2008) Oxaliplatin for metastatic colon cancer in a patient with renal failure. Clin Med Oncol 2:97\u2013101. https:\/\/doi.org\/10.4137\/cmo.s412","journal-title":"Clin Med Oncol"},{"key":"4899_CR10","first-page":"673","volume":"35","author":"S Matoba","year":"2008","unstructured":"Matoba S, Sawada T, Toda S, Moriyama J, Yokoyama T, Ehara K, Mine S et al (2008) Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer. Gan Kagaku Ryoho 35:673\u2013675","journal-title":"Gan Kagaku Ryoho"},{"key":"4899_CR11","first-page":"1379","volume":"36","author":"M Fujita","year":"2009","unstructured":"Fujita M, Koide T, Katayama T, Matsuda H, Yamagishi Y, Okuda M, Kataoka Y (2009) The pharmacokinetics and safety of oxaliplatin in a hemodialysis patient treated with mFOLFOX6 therapy. Gan Kagaku Ryoho 36:1379\u20131382","journal-title":"Gan Kagaku Ryoho"},{"key":"4899_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/jjco\/hyp176","volume":"40","author":"Y Watayo","year":"2010","unstructured":"Watayo Y, Kuramochi H, Hayashi K, Nakajima G, Kamikozuru H, Yamamoto M (2010) Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis. Jpn J Clin Oncol 40:360\u2013364. https:\/\/doi.org\/10.1093\/jjco\/hyp176","journal-title":"Jpn J Clin Oncol"},{"key":"4899_CR13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.clcc.2014.09.003","volume":"13","author":"S Gori","year":"2014","unstructured":"Gori S, Lunardi G, Inno A, Magarotto R, Duranti S, Messa MG, Mucchino C et al (2014) Pharmacokinetics of oxaliplatin in a hemodialyzed patient: chemotherapy dose adjustment and timing of dialysis. Clin Colorectal Cancer 13:260\u2013263. https:\/\/doi.org\/10.1016\/j.clcc.2014.09.003","journal-title":"Clin Colorectal Cancer"},{"key":"4899_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00277-016-2607-0","volume":"95","author":"MS Balzer","year":"2016","unstructured":"Balzer MS, Eggers H, Heuser M, Reising A, Bertram A (2016) Oxaliplatin pharmacokinetics on hemodialysis in a patient with diffuse large B cell lymphoma. Ann Hematol 95:649\u2013650. https:\/\/doi.org\/10.1007\/s00277-016-2607-0","journal-title":"Ann Hematol"},{"key":"4899_CR15","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/jcpt.12661","volume":"43","author":"IRF van Berlo-van","year":"2018","unstructured":"van Berlo-van IRF, Brummelhuis WJ, Imholz ALT, Schellens JH, Huitema ADR, Jansman FGA (2018) Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations. J Clin Pharm Ther 43:574\u2013577. https:\/\/doi.org\/10.1111\/jcpt.12661","journal-title":"J Clin Pharm Ther"},{"key":"4899_CR16","doi-asserted-by":"publisher","first-page":"e17462","DOI":"10.1097\/MD.0000000000017462","volume":"98","author":"D Wang","year":"2019","unstructured":"Wang D, Li X, Xu L, Fang W, Cai X, Wang Y, Wang J et al (2019) Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: a case report. Med (Baltim) 98:e17462. https:\/\/doi.org\/10.1097\/MD.0000000000017462","journal-title":"Med (Baltim)"},{"key":"4899_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/1120009X.2020.1728861","volume":"33","author":"M Maruta","year":"2021","unstructured":"Maruta M, Miyoshi T, Matsuo N, Yamashina T, Irie K, Tsuruta M, Tsukada H et al (2021) Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer. J Chemother 33:51\u201355. https:\/\/doi.org\/10.1080\/1120009X.2020.1728861","journal-title":"J Chemother"},{"key":"4899_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00280-011-1633-9","volume":"68","author":"T Horimatsu","year":"2011","unstructured":"Horimatsu T, Miyamoto S, Morita S, Mashimo Y, Ezoe Y, Muto M, Chiba T (2011) Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. Cancer Chemother Pharmacol 68:263\u2013266. https:\/\/doi.org\/10.1007\/s00280-011-1633-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"4899_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1159\/000502512","volume":"12","author":"C Funasaka","year":"2019","unstructured":"Funasaka C, Kanemasa Y, Shimoyama T, Ohta A, Omuro Y (2019) Modified FOLFOX-6 plus bevacizumab chemotherapy for metastatic colorectal cancer in patients receiving hemodialysis: a report of three cases and review of the literature. Case Rep Oncol 12:657\u2013665. https:\/\/doi.org\/10.1159\/000502512","journal-title":"Case Rep Oncol"},{"key":"4899_CR20","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0090-9556(24)15087-8","volume":"28","author":"P Allain","year":"2000","unstructured":"Allain P, Heudi O, Cailleux A, Le Bouil A, Larra F, Boisdron-Celle M, Gamelin E (2000) Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab Dispos 28:1379\u20131384","journal-title":"Drug Metab Dispos"},{"key":"4899_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","volume":"18","author":"S Giacchetti","year":"2000","unstructured":"Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136\u2013147. https:\/\/doi.org\/10.1200\/JCO.2000.18.1.136","journal-title":"J Clin Oncol"},{"key":"4899_CR22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1248\/bpb.b22-00578","volume":"46","author":"S Nakagawa","year":"2023","unstructured":"Nakagawa S, Shimazaki A, Funakoshi T, Yonezawa A, Kataoka S, Horimatsu T, Hira D et al (2023) Effect of Severe Renal Dysfunction on the Plasma Levels of DNA-Reactive Platinum after Oxaliplatin Administration. Biol Pharm Bull 46:194\u2013200. https:\/\/doi.org\/10.1248\/bpb.b22-00578","journal-title":"Biol Pharm Bull"},{"key":"4899_CR23","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1007\/s10147-025-02832-z","volume":"30","author":"S Nakagawa","year":"2025","unstructured":"Nakagawa S, Ikuta K, Masuda T, Terada T (2025) Onco-nephrology in clinical practice: pharmacokinetics, monitoring, and treatment strategies for patients with cancer and impaired renal function. Int J Clin Oncol 30:1700\u20131706. https:\/\/doi.org\/10.1007\/s10147-025-02832-z","journal-title":"Int J Clin Oncol"},{"key":"4899_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/jns.12432","volume":"26","author":"G Wei","year":"2021","unstructured":"Wei G, Gu Z, Gu J, Yu J, Huang X, Qin F, Li L et al (2021) Platinum accumulation in oxaliplatin-induced peripheral neuropathy. J Peripher Nerv Syst 26:35\u201342. https:\/\/doi.org\/10.1111\/jns.12432","journal-title":"J Peripher Nerv Syst"},{"key":"4899_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1053\/sonc.2002.35525","volume":"29","author":"E Gamelin","year":"2002","unstructured":"Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29:21\u201333. https:\/\/doi.org\/10.1053\/sonc.2002.35525","journal-title":"Semin Oncol"},{"issue":"Suppl 1","key":"4899_CR26","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.3816\/ccc.2005.s.006","volume":"5","author":"A Grothey","year":"2005","unstructured":"Grothey A (2005) Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 5(Suppl 1):S38\u201346. https:\/\/doi.org\/10.3816\/ccc.2005.s.006","journal-title":"Clin Colorectal Cancer"},{"key":"4899_CR27","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/humu.9201","volume":"22","author":"E Gross","year":"2003","unstructured":"Gross E, Ullrich T, Seck K, Mueller V, de Wit M, von Schilling C, Meindl A et al (2003) Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat 22:498. https:\/\/doi.org\/10.1002\/humu.9201","journal-title":"Hum Mutat"},{"key":"4899_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00280-001-0408-0","volume":"49","author":"C Poole","year":"2002","unstructured":"Poole C, Gardiner J, Twelves C, Johnston P, Harper P, Cassidy J, Monkhouse J et al (2002) Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 49:225\u2013234. https:\/\/doi.org\/10.1007\/s00280-001-0408-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"4899_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.4149\/neo_2009_04_303","volume":"56","author":"Z Kleibl","year":"2009","unstructured":"Kleibl Z, Fidlerova J, Kleiblova P, Kormunda S, Bilek M, Bouskova K, Sevcik J et al (2009) Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma 56:303\u2013316. https:\/\/doi.org\/10.4149\/neo_2009_04_303","journal-title":"Neoplasma"},{"key":"4899_CR30","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jmoldx.2024.05.015","volume":"26","author":"VM Pratt","year":"2024","unstructured":"Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, Kalman LV et al (2024) DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium. J Mol Diagn 26:851\u2013863. https:\/\/doi.org\/10.1016\/j.jmoldx.2024.05.015","journal-title":"J Mol Diagn"},{"key":"4899_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1046\/j.1365-2125.2003.01765.x","volume":"55","author":"R Gieschke","year":"2003","unstructured":"Gieschke R, Burger HU, Reigner B, Blesch KS, Steimer JL (2003) Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol 55:252\u2013263. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.01765.x","journal-title":"Br J Clin Pharmacol"},{"key":"4899_CR32","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1053\/ajkd.2002.30584","volume":"39","author":"J Rengelshausen","year":"2002","unstructured":"Rengelshausen J, Hull WE, Schwenger V, Goggelmann C, Walter-Sack I, Bommer J (2002) Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. Am J Kidney Dis 39:E10. https:\/\/doi.org\/10.1053\/ajkd.2002.30584","journal-title":"Am J Kidney Dis"},{"key":"4899_CR33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00280-023-04577-w","volume":"93","author":"H Imamaki","year":"2024","unstructured":"Imamaki H, Oura M, Oguro F, Nishikawa Y, Nakagawa S, Funakoshi T, Kataoka S et al (2024) Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two cases of colorectal cancer patients with end-stage renal failure. Cancer Chemother Pharmacol 93:161\u2013167. https:\/\/doi.org\/10.1007\/s00280-023-04577-w","journal-title":"Cancer Chemother Pharmacol"},{"key":"4899_CR34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00280-017-3249-1","volume":"79","author":"Y Nishikawa","year":"2017","unstructured":"Nishikawa Y, Funakoshi T, Horimatsu T, Miyamoto S, Matsubara T, Yanagita M, Nakagawa S et al (2017) Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. Cancer Chemother Pharmacol 79:629\u2013633. https:\/\/doi.org\/10.1007\/s00280-017-3249-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"4899_CR35","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/00001813-199306000-00003","volume":"4","author":"CC Liaw","year":"1993","unstructured":"Liaw CC, Liaw SJ, Wang CH, Chiu MC, Huang JS (1993) Transient hyperammonemia related to chemotherapy with continuous infusion of high-dose 5-fluorouracil. Anticancer Drugs 4:311\u2013315. https:\/\/doi.org\/10.1097\/00001813-199306000-00003","journal-title":"Anticancer Drugs"},{"key":"4899_CR36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.5414\/CP203762","volume":"58","author":"T Nakamura","year":"2020","unstructured":"Nakamura T, Shibata S, Miyatani Y, Matsubara H (2020) Hyperammonemia with impaired consciousness caused by continuous 5-fluorouracil infusion for colorectal cancer: A case report. Int J Clin Pharmacol Ther 58:727\u2013731. https:\/\/doi.org\/10.5414\/CP203762","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4899_CR37","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00280-020-04158-1","volume":"86","author":"Y Ozaki","year":"2020","unstructured":"Ozaki Y, Imamaki H, Ikeda A, Oura M, Nakagawa S, Funakoshi T, Kataoka S et al (2020) Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses. Cancer Chemother Pharmacol 86:693\u2013699. https:\/\/doi.org\/10.1007\/s00280-020-04158-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"4899_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s004010050482","volume":"92","author":"T Akiba","year":"1996","unstructured":"Akiba T, Okeda R, Tajima T (1996) Metabolites of 5-fluorouracil, alpha-fluoro-beta-alanine and fluoroacetic acid, directly injure myelinated fibers in tissue culture. Acta Neuropathol 92:8\u201313. https:\/\/doi.org\/10.1007\/s004010050482","journal-title":"Acta Neuropathol"},{"key":"4899_CR39","doi-asserted-by":"publisher","first-page":"G206","DOI":"10.1152\/ajpgi.1999.276.1.G206","volume":"276","author":"M Liu","year":"1999","unstructured":"Liu M, Russell RL, Beigelman L, Handschumacher RE, Pizzorno G (1999) beta-alanine and alpha-fluoro-beta-alanine concentrative transport in rat hepatocytes is mediated by GABA transporter GAT-2. Am J Physiol 276:G206\u2013210. https:\/\/doi.org\/10.1152\/ajpgi.1999.276.1.G206","journal-title":"Am J Physiol"},{"key":"4899_CR40","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.4103\/jcrt.jcrt_2165_21","volume":"19","author":"M Manikandan","year":"2023","unstructured":"Manikandan M, Azariah B, Sharma R (2023) 5-Fluorouracil-induced leukoencephalopathy. J Cancer Res Ther 19:2076\u20132078. https:\/\/doi.org\/10.4103\/jcrt.jcrt_2165_21","journal-title":"J Cancer Res Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04899-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04899-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04899-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:11:51Z","timestamp":1778663511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04899-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4899"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04899-5","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"24 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Yuki Nakano, Toshinori Hirai, Nao Nishijo, Yugo Uematsu, Yoko Nakajima, Tomomi Ozaki, Ryoko Shibata, Asako Imada, Kazuya Naritomi, Fumihiko Ogata, Naohito Kawasaki, Tadashi Hayama, Masafumi Yasunaga, Kazuhiro Tada, Hirotsugu Hasuwa, and Kosuke Masutani declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The case report was approved by the Ethics Committee of Saiseikai Futsukaichi Hospital (approval no. 527) and was prepared in accordance with CARE guidelines and the ethical standards of the Declaration of Helsinki and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from the patient.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Patients signed informed consent regarding publishing their data and photographs.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}],"article-number":"50"}}